The KyberSept study of efficacy of high-dose antithrombin therapy in patients with severe sepsis suggests: In the treatment of severe sepsis, high-dose antithrombin may sufficiently protect against development of venous thromboembolism when no concomitant
Human endotoxemia is, at best, an incomplete model of human sepsis. In two studies using recombinant human activated protein C in the setting of human endotoxemia, there were minimal effects on hemodynamics, inflammation, thrombin generation, fibrinolysis
F. Gwadry-Sridhar, A. Hamou, B. Lewden, C. Martin, и M. Bauer. Electronic Healthcare, том 69 из Lecture Notes of the Institute for Computer Sciences, Social Informatics and Telecommunications Engineering, Springer Berlin Heidelberg, (2012)
E. Bouza, A. Burillo, и P. Muñoz. Clinical Microbiology and Infection: The Official Publication of the European Society of Clinical Microbiology and Infectious Diseases, 8 (5):
265--274(мая 2002)PMID: 12047403.